These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1623637)

  • 1. Government initiatives in the development of a pharmaceutical industry in Australia.
    Hirst CA
    Clin Exp Pharmacol Physiol; 1992 Jan; 19(1):57-61. PubMed ID: 1623637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmaceutical industry--prices and progress.
    Scherer FM
    N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
    [No Abstract]   [Full Text] [Related]  

  • 3. No room for compromise. Bill C-22.
    McGillivray D
    CPJ; 1988 Feb; 121(2):88-9. PubMed ID: 10285967
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmaceutical industry: a further study in corporate power.
    McCraine N; Murray MJ
    Int J Health Serv; 1978; 8(4):573-88. PubMed ID: 730410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
    Lexchin J
    Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?
    Drummond M
    Pharmacoeconomics; 1992; 1(Suppl 1):61-9. PubMed ID: 10146934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial drug discovery: is small pharma the solution?
    Boggs AF; Miller GH
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():32-6. PubMed ID: 15522038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotechnology in pharmaceuticals: the Japanese challenge.
    Dibner MD
    Science; 1985 Sep; 229(4719):1230-5. PubMed ID: 3898361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symbiotic relationship between a research institute and a pharmaceutical company: the Baker Institute/Glaxo Australia story.
    Angus JA
    Clin Exp Pharmacol Physiol; 1992 Jan; 19(1):67-71. PubMed ID: 1623639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing prices offered to pharmaceutical purchasing groups.
    Raehtz TR; Milewski R; Massoud N
    Am J Hosp Pharm; 1987 Sep; 44(9):2073-6. PubMed ID: 3674046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current challenges for the pharmaceutical research industry].
    Chalchat B
    Ann Pharm Fr; 1993; 51(1):16-25. PubMed ID: 8215118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The abandonment of antibacterials: why and wherefore?
    Shlaes DM
    Curr Opin Pharmacol; 2003 Oct; 3(5):470-3. PubMed ID: 14559090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do market components account for higher US prescription prices?
    Monaghan MJ; Monaghan MS
    Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vendor competition, generic drugs spur drop in pharmaceutical prices.
    Seigner CA
    Mod Healthc; 1985 Oct; 15(21):56, 60-2. PubMed ID: 10317662
    [No Abstract]   [Full Text] [Related]  

  • 20. Innovation-Innovation Tradeoffs in Drug Pricing.
    Sachs RE; Frakt AB
    Ann Intern Med; 2016 Dec; 165(12):871-872. PubMed ID: 27723887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.